InspireMD Bilan de santé

Santé financière contrôle des critères 6/6

InspireMD possède un total de capitaux propres de $46.8M et une dette totale de $0.0, ce qui porte son ratio d'endettement à 0%. Son actif total et son passif total sont $55.7M et de $8.9M.

Informations clés

Ratio d'endettement

US$0

Dette

Ratio de couverture des intérêts	n/a
Argent liquide	US$47.16m
Fonds propres	US$46.76m
Total du passif	US$8.90m
Total des actifs	US$55.66m

Mises à jour récentes de la santé financière

Recent updates

Analyse de la situation financière

Passif à court terme: Les actifs à court terme de II2 ( $51.8M ) dépassent ses passifs à court terme ( $7.0M ).

Passif à long terme: Les actifs à court terme de II2 ( $51.8M ) dépassent ses passifs à long terme ( $1.9M ).

Historique et analyse du ratio d'endettement

Niveau d'endettement: II2 est sans dette.

Réduire la dette: II2 n'avait aucune dette il y a 5 ans.

Bilan

Analyse des pistes de trésorerie

Pour les entreprises qui ont été en moyenne déficitaires dans le passé, nous évaluons si elles disposent d'au moins un an de trésorerie.

Piste de trésorerie stable: II2 dispose d'une piste de trésorerie suffisante pour plus d'un an sur la base de son flux de trésorerie disponible actuel.

Prévisions de trésorerie: II2 dispose d'une marge de trésorerie suffisante pour 2.4 ans si le flux de trésorerie disponible continue de diminuer à un taux historique de 15.1 % chaque année.

InspireMD Bilan de santé

Santé financière contrôle des critères 6/6

Informations clés

Mises à jour récentes de la santé financière

InspireMD Regains Compliance with NYSE Listing Standards

Recent updates

InspireMD, Inc. to Report Q3, 2024 Results on Nov 12, 2024

InspireMD, Inc. Announces Approval of Investigational Device Exemption (IDE) Application for CGUARDIANS II Pivotal Study of the CGuard Prime 80cm Carotid Stent System

InspireMD Announces Submission of Premarket Approval Application to FDA Seeking U.S. Regulatory Approval of the CGuard™ Prime Carotid Stent System

Second quarter 2024 earnings released: US$0.22 loss per share (vs US$0.24 loss in 2Q 2023)

New major risk - Share price stability

InspireMD, Inc. to Report Q2, 2024 Results on Aug 06, 2024

First quarter 2024 earnings released: US$0.20 loss per share (vs US$0.53 loss in 1Q 2023)

InspireMD, Inc. to Report Q1, 2024 Results on May 14, 2024

Insufficient new directors

InspireMD, Inc., Annual General Meeting, Jun 10, 2024

Full year 2023 earnings released: US$0.82 loss per share (vs US$2.35 loss in FY 2022)

InspireMD, Inc. to Report Q4, 2023 Results on Mar 06, 2024

Insider recently bought €116k worth of stock

Inspiremd, Inc. Presents Positive 30-Day Follow-Up Results from the C-Guard®? U.S. Investigational Device Exemption (Ide) Clinical Trial

InspireMD, Inc. to Report Q3, 2023 Results on Nov 06, 2023

InspireMD, Inc. Announces Management Appointments

Second quarter 2023 earnings released: US$0.24 loss per share (vs US$0.59 loss in 2Q 2022)

InspireMD, Inc., Annual General Meeting, Sep 13, 2023

InspireMD, Inc. to Report Q2, 2023 Results on Aug 08, 2023

InspireMD, Inc. Announces Completion of Enrollment in C-Guardians U.S. Investigational Device Exemption Clinical Trial

InspireMD, Inc. announced that it has received $42.169643 million in funding from Marshall Wace LLP, OrbiMed Advisors LLC, Nantahala Capital Management, LLC, Soleus Capital Management, L.P., Velan Inc. and other investors

InspireMD, Inc. to Report Q1, 2023 Results on May 15, 2023

Third quarter 2022 earnings released: US$0.58 loss per share (vs US$0.53 loss in 3Q 2021)

InspireMD, Inc. to Report Q3, 2022 Results on Nov 08, 2022

Insider recently bought €67k worth of stock

Second quarter 2022 earnings released: US$0.59 loss per share (vs US$0.46 loss in 2Q 2021)

InspireMD, Inc. to Report Q2, 2022 Results on Aug 09, 2022

InspireMD, Inc. Announces Appointment of Endovascular Pioneer Dr. Juan Parodi as Strategic Advisor

InspireMD, Inc., Annual General Meeting, Aug 31, 2022

First quarter 2022 earnings released: US$0.57 loss per share (vs US$0.53 loss in 1Q 2021)

Full year 2021 earnings: Revenues and EPS in line with analyst expectations

InspireMD Announces the Inclusion of its CGuard Carotid Stent in CREST-2 Trial Following FDA Approval of the Investigational Device Exemption Supplement Application

InspireMD, Inc. to Report Q4, 2021 Results on Mar 08, 2022

InspireMD Appoints Adnan Siddiqui as Member of Its Scientific Advisory Board and Strategic Advisor

Insider recently bought €88k worth of stock

Third quarter 2021 earnings released: US$0.53 loss per share (vs US$0.96 loss in 3Q 2020)

Insider recently bought €79k worth of stock

Second quarter 2021 earnings released: US$0.46 loss per share (vs US$2.93 loss in 2Q 2020)

InspireMD Enrolls and Treats First Patients at Ballad Health System in U.S. Registration C-Guardian Clinical Trial of CGuard EPS

First quarter 2021 earnings released: US$0.53 loss per share (vs US$6.42 loss in 1Q 2020)

Full year 2020 earnings released: US$0.47 loss per share (vs US$4.80 loss in FY 2019)

Revenue misses expectations

InspireMD, Inc. to Report Q4, 2020 Results on Mar 09, 2021

InspireMD, Inc. Engages Hart Clinical Consultants to Conduct Clinical Trial for Cguard Carotid Stent System in the United States

InspireMD, Inc. Appoints Chris Metzger as Principal Investigator for CGuard Registration Trial in the United States

New 90-day high: €0.88

InspireMD, Inc. has completed a Composite Units Offering in the amount of $18 million.

InspireMD, Inc. Secures Partner for Intended Registration and Distribution of CGuard EPS in Mainland China

New 90-day high: €0.64

New 90-day high: €0.50

Revenue beats expectations

Third quarter 2020 earnings released: US$0.064 loss per share

Inspiremd, Inc. Appoints Andrea Tommasoli Senior Vice President of Global Sales and Marketing

InspireMD, Inc. to Report Q3, 2020 Results on Nov 09, 2020

InspireMD, Inc. announced that it has received $0.1 million in funding

InspireMD Announces Gary S. Roubin, M.D., Ph.D., to Join Board of Directors

InspireMD, Inc. Appoints Patrick Jamnik as Vice President of Business Development and Strategic Initiatives

InspireMD, Inc. to Report Q3, 2019 Results on Nov 12, 2019

New 90-day low: €0.28

InspireMD, Inc.(AMEX:NSPR) dropped from S&P TMI Index

New 90-day low - €0.32

New 90-day low - €0.35

InspireMD Regains Compliance with NYSE Listing Standards

InspireMD, Inc. to Report Q2, 2020 Results on Aug 05, 2020

Analyse de la situation financière

Historique et analyse du ratio d'endettement

Bilan

Analyse des pistes de trésorerie

Découvrir des entreprises saines